Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Since an investor revolt early this year at Air Products and Chemicals, the new leadership at the industrial gas giant has ...

Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is bouncing back and has performed well in recent months. What's more, there ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 11.76% on an annualized basis producing an average annual return of 23.85%. Currently, Regeneron ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

Regeneron Pharmaceuticals (REGN) has received approval from the European Commission for Libtayo (cemiplimab), to be used as an adjuvant treatment for adults with cutaneous squamous cell carcinoma ...

Broadcom Stock dropped 20% after a strong rally. Analysts highlight earnings growth, dividend boost and long-term AI demand ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for the latter’s TSRA-196. Both companies will jointly develop Tessera’s lead ...